Drug interaction study in healthy volunteers
Treatments studied
Part of Lungs & breathing clinical trials.
This trial studies how a new drug (HRS-9813) interacts with two existing lung fibrosis drugs (pirfenidone and nintedanib) in healthy adults. The results will help doctors understand how to combine these medicines safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 45 years old.
- Weigh at least 50 kg (men) or 45 kg (women), with a body mass index (BMI) between 19 and 28.
- Be willing to avoid pregnancy and use effective non-drug contraception for 28 days after the last dose.
- Not smoke more than 5 cigarettes a day, and be willing to stop using any tobacco during the trial.
- Have no allergies to the study drugs or conditions like asthma, allergic rhinitis, or eczema.
- Not have any serious infections, surgeries, or recent participation in other drug trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This is an early-stage safety and tolerability study of a new drug called HW241045 in healthy volunteers. Researchers will test the drug at different doses to understand how the body processes it and what side effects it may cause.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.